Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $15.2 million.

  • Barinthus Biotherapeutics' Operating Expenses fell 3801.86% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.1 million, marking a year-over-year increase of 314.55%. This contributed to the annual value of $84.1 million for FY2024, which is 70.94% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Operating Expenses is $15.2 million, which was down 3801.86% from $23.3 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' Operating Expenses registered a high of $31.6 million during Q4 2022, and its lowest value of -$1.1 million during Q3 2022.
  • Moreover, its 5-year median value for Operating Expenses was $17.1 million (2024), whereas its average is $17.0 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 11927.99% in 2022, then surged by 160373.48% in 2023.
  • Over the past 5 years, Barinthus Biotherapeutics' Operating Expenses (Quarter) stood at $16.7 million in 2021, then skyrocketed by 89.3% to $31.6 million in 2022, then tumbled by 36.65% to $20.0 million in 2023, then grew by 17.94% to $23.6 million in 2024, then plummeted by 35.43% to $15.2 million in 2025.
  • Its last three reported values are $15.2 million in Q3 2025, $23.3 million for Q2 2025, and $20.9 million during Q1 2025.